Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disorder of the connective tissue characterized by progressive disability as a result of extensive extra skeletal enchondral bone formation and malformed big toes which are often monophalangic. Occasional features include short thumbs, fifth finger clinodactyly, malformed cervical vertebrae and mild mental retardation. Beginning during childhood, FOP progressively immobilizes all the joints through adult life, rendering movement impossible. Currently, there is no effective prevention or cure for this debilitating disease. Since it has an autosomal dominant inheritance, our concern is to highlight prompt genetic counseling in the concerned families although many sporadic cases have also been identified.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Hearing loss predictive model in fibrodysplasia ossificans progressiva from a national referral center: developing an hearing loss predictive model.
JBMR Plus
April 2025
Otorhinolaryngology Unit, IRCCS Istituto Giannina Gaslini, 16132 Genova, Italy.
Fibrodysplasia ossificans progressiva (FOP) is the most dramatic form of progressive heterotopic ossification of soft tissues. Hearing impairment in FOP patient is a common feature, reported by about 50% of affected patients. However, wide case series considering audiologic features are lacking.
View Article and Find Full Text PDFInsights Gained From an Ultrarare Case of Progressive Osseous Heteroplasia With Severe Complications.
Cureus
January 2025
Internal Medicine, Coimbra Local Health Unit (ULS Coimbra), Coimbra, PRT.
Progressive osseous heteroplasia (POH) is an exceptionally rare genetic disorder characterized by progressive heterotopic ossification of cutaneous, subcutaneous, and deep connective tissues. Most cases are associated with paternally inherited inactivating mutations in the guanine nucleotide-binding protein, alpha-stimulating gene. However, the genetic basis remains undefined in a subset of patients, adding further complexity to its pathogenesis.
View Article and Find Full Text PDFEarly Detection for Better Patient Outcome: A Case Report on Two Patients Presenting With Fibrodysplasia Ossificans Progressiva at Tikur Anbessa Specialized Hospital, Ethiopia.
Case Rep Orthop
January 2025
Tikur Anbessa Specialized Hospital, Department of Orthopaedics, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Fibrodysplasia ossificans progressiva is an ultrarare disorder of endochondral ossification. It is unfamiliar to most care providers in low-income countries such as Ethiopia. Even though the clinical presentation is typical, most cases remain misdiagnosed in our region.
View Article and Find Full Text PDFPalovarotene in fibrodysplasia ossificans progressiva: review and perspective.
Expert Opin Pharmacother
February 2025
Department of Internal Medicine, Section Endocrinology and Metabolism - Rare Bone Disease Center, Amsterdam University Medical Center (Amsterdam UMC), location VU University Medical Center (VUMC), Amsterdam, Netherlands.
Introduction: Palovarotene is a retinoic acid receptor gamma agonist that was studied in phase-2 and phase-3 clinical trials for the inhibition of new heterotopic ossification (HO) in fibrodysplasia ossificans progressiva (FOP). Despite numerous setbacks and regulatory delays, palovarotene is now the first approved FOP treatment in the U.S.
View Article and Find Full Text PDFThe 24 Annual Santa Fe Bone Symposium (SFBS) was held in Santa Fe, New Mexico, USA, on August 2-3, 2024. This was a "hybrid" meeting, with in-person and real-time remote participants representing a broad range of geographical locations and medical disciplines. The focus was on new developments in the care of patients with osteoporosis, other metabolic bone diseases, and inherited skeletal disorders.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!